Kite Pharma (KITE): ZUMA-1 Data Creates First Mover Advantage - Stifel

September 27, 2016 7:51 AM EDT
Get Alerts KITE Hot Sheet
Price: $45.89 +1.82%

Rating Summary:
    15 Buy, 2 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade KITE Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Stifel analyst, Thomas Shrader, reiterated his Buy rating on shares of Kite Pharma (NASDAQ: KITE) after the company released topline data from ZUMA-1 that were considerably better than the standard of care (SOC) with a CR rate of 52% relative to the current SOC (salvage chemotherapies) that would be expected to yield a CR rate of about 8%.

The analyst sees these results as above the expected bar for approval - which physicians familiar with these patients set at about a CR rate of 25%. That being said, it looks like early days in the use of these cells as about of the 25% patients that initially achieve a CR loose their responses within three months (durable-CR rate of 39%). These pseudo-CRs seem to be the low hanging fruit in upcoming efforts to improve the efficacy of KTE-019 and more experienced treaters may be able to close this gap over time. Most importantly, Kite should now enjoy a significant first mover advantage as we expect this learning process to occur in the commercial setting using Kite’s product.

No change to the price target of $74.

For an analyst ratings summary and ratings history on Kite Pharma click here. For more ratings news on Kite Pharma click here.

Shares of Kite Pharma closed at $54.98 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA

Related Entities

Stifel

Add Your Comment